SEARCH

SEARCH BY CITATION

References

  • Auriola, S., J. C. Frith, M. J. Rogers, A. Koivuniemi & J. Mönkkönen: Identification of adenine nucleotidi-containing metabolites of bisphosphonate drugs using ion-pair liquid choromatography-electrospray mass spectrometry. J. Cromatogr. 1997, 704, 187195.
  • Beek, V. B., C. Löwik, I. Que & S. Papapoulos: Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by subtitution of the hydroxyl with an amino group. J. Bone Miner. Res. 1996, 11, 14921497.
  • Benford, H. L., N. W. A. McGowan, M. H. Helfrich, M. E. Nuttall & M. J. Rogers: Visualization of bisphosphonates-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001, 5, 465473.
  • Body, J. J.: Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. Breast 2003, 12 (Suppl 2), 3744.
  • Boyde, A., N. N. Ali & S. J. Jones: Resorption of dentine by isolated osteoclasts in vitro. Brit. Dent. J. 1984, 156, 216220.
  • Brown, R. J., E. Van Beek, D. J. Watts, C. W. Lowik & S. E. Papapoulos: Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum. J. Bone Miner. Res. 1998, 13, 253258.
  • Carano, A., S. L. Teitelbaum, J. D. Konsek, P. H. Schlesinger & H. C. Blair: Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J. Clin. Invest. 1990, 85, 456461.
  • Chambers, T. J., B. M. Thomson & K. Fuller: Effect of substrate composition on bone resorption by rabbit osteoclasts. J. Cell Sci. 1984, 70, 6171.
  • Cremers, S. C., M. E. Eekhoff, J. Den Hartigh, N. A Hamdy, P. Vermeij & S. E. Papapoulos: Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget`s disease of bone. J. Bone Miner. Res. 2003, 18, 868875.
  • Fisher, J. E., G. A. Rodan & A. A. Reszka: In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000, 141, 47934796.
  • Frith, J. C., J. Mönkkönen, S. Auriola, H. Monkkonen & M. J. Rogers: The molecular mechanism of action of antiresorptive and anti-inflammatory drug clodronate: evidence for the formation in vivo of metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Art. Rheum. 2001, 44, 22012210.
  • Frith, J. C., J. Mönkkönen, G. M. Blackburn, G. G. G. Russell & M. J. Rogers: Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β,γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J. Bone Miner. Res. 1997, 12, 13581367.
  • Fromigue, O. & J. J. Body: Bisphosphonates influence the proliferation and maturation of normal human osteoblasts. J. Endocrinol. Invest. 2002, 25, 539546.
  • Green, J. R.: Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin. Oncol. 2001, 28 (Suppl 2), 410.
  • Green, J. R., K. Müller & K. A. Jaeggi: Preclinical pharmacology of CGP 42`446 a new potent heterocyclic bisphosphonate compound. J. Bone Miner. Res. 1994, 9, 745751.
  • Halasy-Nagy, J. M., G. A. Rodan & A. A. Reszka: Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 2001, 29, 553559.
  • Hilding, M., L. Ryd, S. Toksvig-Larsen & P. Aspenberg: Clodronate prevents prosthetic migration. Acta Orthop. Scand. 2000, 71, 553557.
  • Hughes, D. E., K. R. Wright, H. L. Uy, A. Sasaki, T. Yoneda, G. D. Roodman, G. R. Mundy & B. F. Boyce: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 1995, 10, 14781487.
  • Hyldstrup, L., G. Flesch & S. A. Hauffe: Pharmacokinetic evaluation of pamidronate after oral administration: a study on dose proportionality, absolute bioavailability, and effect of repeated administration. Calcif. Tissue Int. 1993, 53, 297300.
  • Im, G. I., S. A. Qureshi, J. Kenney, H. E. Rubash & A. S. Sanhbag: Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004, 25, 41054115.
  • Komarova, S. V., J. B. Shum, L. A. Paige, S. M. Sims & S. J. Dixon: Regulation of osteoclasts by calcitonin and amphiphilic calcitonin conjugates: role of cytosolic calcium. Calcif. Tissue Int. 2003, 73, 265273.
  • Lehenkari, P. P., M. Kellinsalmi, J. N. Näpänkangas, K. V. Ylitalo, J. Mönkkönen, M. J. Rogers, A. Azhayev, H. K. Väänänen & I. E. Hassinen: Further insight into mechanism of action of clodronate: Inhibition of mitochodrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol. 2002, 61, 12551262.
  • Leskelä, H. V., J. Risteli, S. Niskanen, J. Koivunen, K. K. Ivaska & P. Lehenkari: Osteoblast recruitment from stem cells does not decrease by late adulthood. Biochem. Biophys. Res. Commun. 2003, 311, 10081013.
  • Major, P.: The use of zoledronic acid a novel highly potent bisphosphonate for the treatment of hypercalcemia of malignancy. The Oncologist 2002, 7, 481491.
  • Mayahara, M. & T. Sasaki: Cellular mechanism of inhibition of osteoclastic resorption of bone and calcified cartilage by long-term pamidronate administration in ovariectomized mature rats. Anat. Rec. 2003, 274a, 817826.
  • Mönkkönen, H., P. Lehenkari, M. Kellinsalmi, I. Hassinen, S. Auriola, J. Vepsäläinen & J. Mönkkönen: Nitrogen-containing bisphosphonates cause intracellular accumulation of isopentenyl diphosphate (IPP) and biosynthesis of ApppI. Bone 2004a, 34 (Suppl 1), 67.
  • Mönkkönen, H., P. Lehenkari, M. Kellinsalmi, I. Hassinen, S. Auriola, J. Vepsäläinen & J. Mönkkönen: A new mechanism of action for bisphosphonates: ApppI mediated cytotoxity of N-BPs. Bone 2004b, 34 (Suppl 1), 66.
  • Mönkkönen, H., M. J. Rogers, N. Makkonen, S. Niva, S. Auriola & J. Mönkkönen: The cellular uptake and metabolism of clodronate in RAW 264 macrophages. Pharm. Res. 2001, 18, 15501555.
  • Nishikawa, M., T. Akatsu, Y. Katayama, Y. Yasutomo, S. Kado, N. Kugai, M. Yamamoto & N. Nagata: Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996, 18, 914.
  • Plotkin, L. I., R. S. Weinstain, A. M. Parfitt, P. K. Roberson, S. C. Manolagas & T. Bellido: Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Invest. 1999, 104, 13631374.
  • Porras, A. G., S. D. Holland & B. J. Gertz: Pharmacokinetics of alendronate. Clin. Pharmacokin. 1999, 36, 315328.
  • Rauch, F., R. Travers, H. Plotkin & F. H. Glorieux: The effects of intravenous pamidronate on the bone tissue of children and adolescent with osteogenesis imperfecta. J. Clin. Invest. 2002, 110, 12931299.
  • Reid, I. R., J. P. Brown, P. Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel, A. Widmer, J. P. Devogelaer, J. M. Kaufman, P. Jaeger, J. J. Body, M. L. Brandl, J. Broell, R. Di Micco, A. R. Genazzani, D. Felsenberg, J. Happ, M. J. Hooper, J. Ittner, G. Leb, H. Mallmin, T. Murray, S. Ortolani, A. Rubinacci, M. Saaf, G. Samsioe, L. Verbruggen & P. J. Meunier: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New Engl. J. Med. 2002, 346, 653661.
  • Reinholz, G. G., B. Getz, E. S. Sanders, M. Y. Karpeisky, N. Sh. Padyukova, S. N. Mikhailov, J. N. Inge & T. C. Spelsberg: Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue. Breast Cancer Res. Treat. 2002, 71, 257268.
  • Reszka, A. A., J. M. Halasy-Nagy, P. J. Masarachia & G. A. Rodan: Bisphophonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. J. Biol. Chem. 1999, 274, 3496734973.
  • Rogers, M. J.: New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 2003, 9, 26432658.
  • Rogers, M. J., S. Gordon, H. L. Benford, F. P. Coxon, S. P. Luckman, J. Mönkkönen & J. C. Frith: Cellular and molecular mechanism of action of bisphosphonates. Cancer 2000, 88 (Suppl 12), 29612978.
  • Russell, R. G., M. J. Rogers, J. C. Frith, S. P. Luckman, F. P. Coxon, H. L. Benford, P. I. Croucher, C. Shipman & H. A. Fleisch: The pharmacology of bisphosphonates and new insights into their mechanism of action. J. Bone Miner. Res. 1999, 14 (Suppl 2), 5365.
  • Selander, K. S., P. L. Härkönen, J. Mönkkönen, E. K. Karhukorpi, R. Hannuniemi & H. K. Väänänen: Characteristics of clodronate-induced apoptosis in osteoclast macrophages. Mol. Pharmacol. 1996, 50, 11271138.
  • Selander, K., P. Lehenkari & H. K. Vaananen: The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif. Tissue Int 1994, 55, 368375.
  • Suri, S., J. Mönkkönen, M. Taskinen, J. Pesonen, M. A. Blank, R. J. Phipps & M. J. Rogers: Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxity. Bone 2001, 29, 336343.
  • Van Beek, E. R., L. H. Cohen, I. M. Leroy, F. H. Ebetino, C. W. G. M. Löwik & S. E. Papapoulos: Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003, 33, 805811.
  • Villikka, K., K. Perttunen, J. Rosnell, H. Ikävalko, H. Vaho & L. Pylkkänen: The absolute bioavailability of clodronate from two different oral doses. Bone 2002, 31, 418421.
  • Yakatan, G. J., W. J. Poynor, R. L. Talbert, B. F. Floyd, C. L. Slough, R. S. Ampulski & J. J. Benedict: Clodronate kinetics and bioavailability. Clin. Pharmacol. Therap. 1982, 31, 402410.